People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, ...

Researchers analyzed 11 different studies to understand weight outcomes after stopping anti-obesity medications called ...

The appetite-suppressing medications reduce consumption of processed and sugary foods, creating new risks and opportunities.

West Pharmaceutical stock was climbing 19% on Thursday, putting it on track for the strongest single-day percentage increase ...

Longer treatment duration, not having diabetes, and using semaglutide are among the factors linked to better weight reduction over 12 months.

The hormonal changes of menopause can make the weight gain more resistant to traditional diet and lifestyle changes. But GLP-1s can be an effective reinforcement of diet and exercise.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

Pediatric endocrinologist Dr. Casey Berman says GLP-1s may help children reduce their risk of developing serious health ...

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure increasing danger of macular degeneration.

More and more research indicates that GLP-1 analogues can have a blunting effect on addictions like drugs and alcohol. Drug ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Fibromyalgia patients taking GLP-1s have lower rates of opioid use, pain, fatigue, and malaise in a real-world patient data analysis.